Get Your Personalized Supplement StackSupplement Stack Quiz

Proprietary Weight Loss Formulation

Also known as: Proprietary Weight Loss Formulation, Proprietary weight loss blends, Proprietary alpha-amylase inhibitors, White kidney bean extract (WKBE), Phase 2®, Phaseolus vulgaris alpha-amylase inhibitor

Overview

Proprietary Weight Loss Formulations are dietary supplements designed to aid weight management, often by reducing calorie absorption or enhancing metabolism. While the term 'proprietary' implies varied compositions, a well-researched example is the alpha-amylase inhibitor derived from Phaseolus vulgaris, commonly known as white kidney bean extract. This specific compound functions by inhibiting the digestive enzyme alpha-amylase, thereby reducing the breakdown and absorption of complex carbohydrates. These formulations are primarily used to promote weight loss, particularly by mitigating the caloric impact of starch-rich foods. Research on these blends is moderate; while some, like white kidney bean extract, have undergone systematic reviews and meta-analyses showing modest benefits, many multi-ingredient proprietary blends lack independent, high-quality evidence. The overall evidence quality is mixed, with studies on alpha-amylase inhibitors indicating statistically significant, albeit modest, weight loss benefits, often requiring concurrent dietary and lifestyle changes for optimal results.

Benefits

The primary benefit of Phaseolus vulgaris alpha-amylase inhibitor supplementation is modest but statistically significant weight loss. Meta-analyses indicate an average weight loss of approximately -1.08 kg compared to placebo, with a significant reduction in body fat of about -3.26 kg. These effects are observed over intervention periods, typically 8-12 weeks. While some studies suggest improvements in waist circumference and metabolic markers, these secondary effects are less consistently reported. The benefits are most pronounced in overweight or obese adults and are often enhanced when combined with calorie restriction or increased physical activity. It's important to note that while statistically significant, the effect sizes are modest and may not alone achieve clinically relevant weight loss (typically >5% body weight reduction). The evidence quality for white kidney bean extract is moderate to high, supported by multiple systematic reviews and meta-analyses, though heterogeneity among studies exists.

How it works

Phaseolus vulgaris alpha-amylase inhibitors primarily function by blocking the activity of the alpha-amylase enzyme in the digestive tract. This enzyme is responsible for breaking down complex carbohydrates (starches) into simpler sugars that can be absorbed by the body. By inhibiting alpha-amylase, the supplement reduces the digestion and subsequent absorption of dietary carbohydrates, effectively lowering the caloric intake from starch-containing meals. This mechanism acts locally within the gastrointestinal lumen, with minimal systemic absorption of the active compounds. The effect is directly on the enzyme, preventing the breakdown of starches before they can be absorbed into the bloodstream.

Side effects

Proprietary weight loss formulations, particularly those containing Phaseolus vulgaris alpha-amylase inhibitors, are generally well tolerated. The most common side effects, occurring in over 5% of users, are mild gastrointestinal symptoms such as bloating, flatulence, and diarrhea. These symptoms arise from the fermentation of undigested carbohydrates in the colon. Uncommon side effects (1-5%) include rare allergic reactions, though these are not frequently reported. Serious adverse events are rare, with no consistent reports in clinical trials. While no major drug interactions have been documented, caution is advised for individuals taking diabetes medications due to the potential for additive effects on blood glucose levels. The supplement is contraindicated for individuals with known allergies to legumes or alpha-amylase inhibitors. Safety during pregnancy, lactation, and in children has not been well established, and therefore, use in these populations is not recommended.

Dosage

For Phaseolus vulgaris alpha-amylase inhibitors, studies typically use doses ranging from 500 mg to 3 grams per day of standardized extract. The optimal dosage appears to be around 1,000–3,000 mg daily, divided and administered before carbohydrate-containing meals to maximize enzyme inhibition. There is no well-defined maximum safe dose, but doses up to 3 grams per day have generally been well tolerated in clinical trials. The timing of administration is crucial; the supplement should be taken immediately before or with meals rich in carbohydrates to be effective. It is typically available in capsule or tablet form, standardized for its alpha-amylase inhibitor content. The effectiveness is dependent on the presence of dietary carbohydrates for the enzyme to act upon.

FAQs

Is it safe?

Generally, yes. Most users experience mild gastrointestinal side effects like bloating or gas due to undigested carbohydrates. Serious side effects are rare.

How soon do results appear?

Weight loss effects are typically observed within 8 to 12 weeks of consistent use, especially when combined with dietary changes and exercise.

Can it replace diet and exercise?

No, it cannot. These formulations are best used as an adjunct to a healthy diet and regular exercise, not as a replacement for them.

Are all proprietary formulations equal?

No. The efficacy varies significantly depending on the specific ingredients, their concentrations, and the quality of the formulation. Research primarily supports white kidney bean extract.

Does it cause fat loss or just water weight?

Research, particularly on white kidney bean extract, indicates that it contributes to actual fat mass reduction, not just temporary water weight loss.

Research Sources

https://www.nature.com/articles/s41598-022-15770-x – This systematic review and meta-analysis examined weight loss in control groups of randomized controlled trials, highlighting the importance of robust control conditions in weight management research. While not specific to proprietary formulations, it underscores the need for rigorous methodology in assessing weight loss interventions.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5920428/ – This meta-analysis of randomized controlled trials investigated the effects of Phaseolus vulgaris alpha-amylase inhibitor on body weight and fat. It found a statistically significant average weight loss of -1.08 kg and fat loss of -3.26 kg compared to placebo, supporting its role in weight management. Limitations included moderate heterogeneity and small sample sizes.
https://www.nature.com/articles/s41598-024-63443-8 – This systematic review and meta-analysis focused on white kidney bean extract, finding significant body fat reduction but inconsistent weight loss across studies. It emphasized the importance of compliance and dietary control for effective outcomes, suggesting that while promising, results can vary based on study design and participant adherence.